Skip to content
Triangle logo TriangleGet started
← Study library

NCT02560298 · CITED IN SOURCE DOCUMENTS

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
UNKNOWN
Registry last update
2023-06-22

This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin and fluorouracil are more effective than carboplatin and paclitaxel in treating anal cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Inoperable, locally recurrent or metastatic disease (tumor resectability should be assessed by a local surgeon or multidisciplinary team) * Histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion * Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2 * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 * Previous definitive chemo-radiation is permitted for early stage tumors (cisplatin-based chemotherapy \[chemo\]-radiation is permitted but only if tumor progression/relapse occurs after 6 months from treatment completion) * Previous systemic chemotherapy is permitted if administered as induction treatment (=\< 2 cycles) before definitive chemoradiotherapy for early stage disease and there is no evidence of tumor progression during or after treatment completion * Human immunodeficiency virus positive (HIV+) patients will be considered eligible if they are on highly active anti-retroviral therapy (HAART) and have a cluster of differentiation (CD)4 count of \>= 200/ul (HIV+ patients who are on HAART and have a CD4 count \< 200/ul are eligible if the plasma viral load is below the level of detection according to the local assay) * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/l * Platelets \>= 100 x 10\^9/l * Hemoglobin (Hb) \>= 9 g/dl for males and \>= 8 g/dl for females * Creatinine clearance \>= 50 ml/minute * Serum bilirubin =\< 1.5 x upper limit of normal (ULN) * Alanine transaminase (ALT) or aspartate transaminase (AST) =\< 3 x ULN (if liver metastases are present, serum transaminases =\< 5 x ULN are permitted) * Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy * Life expectancy of at least 3 months Exclusion Criteria: * Tumors of adenocarcinoma, melanoma, small cell and basal cell histology are excluded * Locally recurrent tumor which is amenable to curative resection (as deemed by a local surgeon or multidisciplinary team) * Tumor relapse/progression within 6 months of completion of a cisplatin-based chemoradiotherapy regimen for the treatment of early stage tumors * Previous administration of \> 2 cycles of systemic chemotherapy as induction treatment before definitive chemoradiotherapy for early stage disease * Tumor progression during or immediately after completion of =\< 2 cycles of systemic chemotherapy as induction treatment before definitive chemoradiotherapy for early stage disease * Previous use of systemic chemotherapy or other investigational drugs for the treatment of inoperable locally recurrent or metastatic tumors (previous use of radiotherapy in this setting is not an exclusion criterion if: 1) non-irradiated target tumor lesions are present at randomization for the purpose of tumor response assessment or 2) in the absence of non-irradiated target tumor lesions, progression of the irradiated tumor lesions according to the RECIST criteria version 1.1 is documented) * Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study * Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease * Major surgery performed \< 28 days from treatment start * Palliative radiotherapy completed =\< 7 days from treatment start * Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months); any history of clinically significant cardiac failure * History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan * HIV+ patients who are not on HAART or have a CD4 count of \< 200/ul in the presence of detectable plasma viral load according to the local assay * Known history of active hepatitis B or hepatitis C infection * Serious active infection requiring intravenous (i.v.) antibiotics at enrollment * Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer * Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial * Known hypersensitivity to any of the study drugs or excipients * Known peripheral neuropathy \> grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible) * Pre-existing hearing impairment * Patients planning for a live vaccine * Pregnant or lactating females
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
    intervention Names
    1. Drug: Capecitabine
    2. Drug: Cisplatin
    3. Drug: Fluorouracil
    4. Other: Laboratory Biomarker Analysis
    5. Other: Quality-of-Life Assessment
    label
    Arm A (cisplatin, fluorouracil or capecitabine)
    type
    EXPERIMENTAL
  2. description
    Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: Carboplatin
    2. Other: Laboratory Biomarker Analysis
    3. Drug: Paclitaxel
    4. Other: Quality-of-Life Assessment
    label
    Arm B (paclitaxel, carboplatin)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm A (cisplatin, fluorouracil or capecitabine)
    name
    Capecitabine
    other Names
    1. Ro 09-1978/000
    2. Xeloda
    type
    DRUG
  2. arm Group Labels
    1. Arm B (paclitaxel, carboplatin)
    description
    Given IV
    name
    Carboplatin
    other Names
    1. Blastocarb
    2. Carboplat
    3. Carboplatin Hexal
    4. Carboplatino
    5. Carbosin
    6. Carbosol
    7. Carbotec
    8. CBDCA
    9. Displata
    10. Ercar
    11. JM-8
    12. Nealorin
    type
    DRUG
  3. arm Group Labels
    1. Arm A (cisplatin, fluorouracil or capecitabine)
    description
    Given IV
    name
    Cisplatin
    other Names
    1. Abiplatin
    2. Blastolem
    3. Briplatin
    4. CDDP
    5. Cis-diammine-dichloroplatinum
    6. Cis-diamminedichloridoplatinum
    7. Cis-diamminedichloro Platinum (II)
    8. Cis-diamminedichloroplatinum
    9. Cis-dichloroammine Platinum (II)
    10. Cis-platinous Diamine Dichloride
    11. Cis-platinum
    12. Cis-platinum II
    type
    DRUG
  4. arm Group Labels
    1. Arm A (cisplatin, fluorouracil or capecitabine)
    description
    Given IV
    name
    Fluorouracil
    other Names
    1. 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
    2. 5-Fluorouracil
    3. 5-Fluracil
    4. 5-FU
    5. AccuSite
    6. Carac
    7. Fluoro Uracil
    8. Fluouracil
    9. Flurablastin
    10. Fluracedyl
    11. Fluracil
    12. Fluril
    type
    DRUG
  5. arm Group Labels
    1. Arm A (cisplatin, fluorouracil or capecitabine)
    2. Arm B (paclitaxel, carboplatin)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  6. arm Group Labels
    1. Arm B (paclitaxel, carboplatin)
    description
    Given IV
    name
    Paclitaxel
    other Names
    1. Anzatax
    2. Asotax
    3. Bristaxol
    4. Praxel
    5. Taxol
    6. Taxol Konzentrat
    type
    DRUG
  7. arm Group Labels
    1. Arm A (cisplatin, fluorouracil or capecitabine)
    2. Arm B (paclitaxel, carboplatin)
    description
    Ancillary studies
    name
    Quality-of-Life Assessment
    other Names
    1. Quality of Life Assessment
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
91
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Multivariate analyses will be performed to evaluate the effect of known prognostic factors and biomarkers on outcomes observed.
    measure
    Changes in expression of tumor biomarkers
    time Frame
    Up to 3 years
primary Outcomes
  1. description
    The ORR will be summarized as the percentage (including 95% confidence intervals) of responders and presented by treatment group and will be compared (as exploratory endpoint) between treatment groups using a chi-squared test.
    measure
    Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1
    time Frame
    Up to 3 years
secondary Outcomes
  1. description
    Anti-tumor activity and magnitude of response will be captured by waterfall plot analyses. The percentage change in tumor size from baseline to the time of best response will be plotted by patients (ordered from worst to best) and bars colored according to best response.
    measure
    Anti-tumor activity and magnitude of response
    time Frame
    Up to 3 years
  2. description
    The ORR of non-irradiated lesions will be summarized as the percentage (including 95% confidence intervals) of responders and presented by treatment group and will be compared (as exploratory endpoint) between treatment groups using a chi-squared test.
    measure
    Best ORR of non-irradiated lesions defined as the percentage of patients achieving confirmed PR or CR as per RECIST v1.1 of non-irradiated sites of disease
    time Frame
    Up to 3 years
  3. description
    QOL will be evaluated using the European Organization for Research and Treatment of Cancer Core Quality of Life and EuroQOL-5 dimension-5 level questionnaires. Differences from baseline will be compared between arms of the study using the two sample t-test or Wilcoxon non-parametric method as appropriate.
    measure
    Changes in QOL
    time Frame
    Baseline to up to 3 years
  4. description
    DCR will be summarized as the percentage (including 95% confidence intervals) of responders and presented by treatment group and will be compared (as exploratory endpoint) between treatment groups using a chi-squared test.
    measure
    DCR defined as CR, PR, or SD assessed according to RECIST criteria v1.1
    time Frame
    At 24 weeks post treatment start
  5. description
    DCR will be summarized as the percentage (including 95% confidence intervals) of responders and presented by treatment group and will be compared (as exploratory endpoint) between treatment groups using a chi-squared test.
    measure
    DCR defined as CR, PR, or stable disease (SD) assessed according to RECIST criteria v1.1
    time Frame
    At 12 weeks post treatment start
  6. description
    The proportion of centers engaging will be presented with 95% confidence intervals.
    measure
    Feasibility in terms of proportion of centers that successfully recruit at least one patient
    time Frame
    Up to 36 months
  7. description
    The recruitment rate will be calculated overall centers and by country and center.
    measure
    Feasibility in terms of recruitment rate
    time Frame
    Up to 36 months
  8. description
    The Kaplan Meier estimates of OS over time and median OS with associated 95% confidence intervals will be presented by treatment and (as exploratory endpoint) compared using a log rank test. Cox multivariate regression analysis will be used (as exploratory analysis) to calculate the hazard ratio between treatments along with its 95% confidence interval. The treatment effect will be adjusted for the stratification factors and other identified prognostic factors (e.g. time to disease relapse \& whether pre-treated with platinum) in a multivariate setting.
    measure
    OS
    time Frame
    From the date of randomization to the date of death from any cause, assessed up to 12 months
  9. description
    The Kaplan Meier estimates of PFS over time and median PFS with associated 95% confidence intervals will be presented by treatment and (as exploratory endpoint) compared using a log rank test. Cox multivariate regression analysis will be used (as exploratory analysis) to calculate the hazard ratio between treatments along with its 95% confidence interval. The treatment effect will be adjusted for the stratification factors and other identified prognostic factors (e.g. time to disease relapse \& whether pre-treated with platinum) in a multivariate setting.
    measure
    PFS
    time Frame
    From the date of randomization to the date of confirmed clinical/radiological progression or death from any cause, assessed up to 12 months
  10. description
    The proportion of patients experiencing grade 3-5 toxicity will be compared on a regimen basis using the chi-squared test. Fisher's exact test will be used when expected cell frequencies are \< 5.
    measure
    Proportion of patients experiencing grade 3-5 toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
    time Frame
    Up to 3 years
  11. measure
    Sensitivity analysis of ORR
    time Frame
    Up to 3 years
Full study description
brief Summary
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same place as the primary tumor, or spread to other places in the body. Drugs used in chemotherapy, such as cisplatin, fluorouracil, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin and fluorouracil are more effective than carboplatin and paclitaxel in treating anal cancer.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate best overall response rate (ORR). SECONDARY OBJECTIVES: I. Overall survival (OS). II. Progression free survival (PFS). III. Disease control rate (DCR) (stable disease \[SD\] or better) at 12 and 24 weeks. IV. Best ORR of non-irradiated lesions. V. Anti-tumor activity and magnitude of response as captured by waterfall plot analyses. VI. Toxicity. VII. Quality of life (QOL). VIII. Feasibility of conducting a multicenter international study on squamous cell carcinoma of the anus (SCCA) and recruit within a reasonable time frame. TERTIARY OBJECTIVES: I. Explorative biomarker analysis. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive cisplatin intravenously (IV) over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator may receive capecitabine twice daily (BID) on days 1-4. ARM B: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 12 weeks.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-ba33d2faf751bc861e52
      requested nct id
      NCT02560298
      primary nct id
      NCT02560298
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      c54648d582057bfbec7e0e68f1a07a9ab6a29dd4c399f12d1b7bf097f6c59d27
      payload sha256
      1a05060cb641bf980efddccf61f6899d21a28adfbdbebc255615495babeee5a5
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-ba33d2faf751bc861e52
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT02560298
      occurrences
      1. context exact
        4> <div class="pdq-content-list"><ol id="_420"><li>In the multicenter, randomized, phase II International Advanced Anal Cancer <a href="/clinicaltrials/NCT02560298">InterAACT</a> trial (NCT02560298), carboplatin (area under the curve 5) and weekly paclitaxel was compared with standard infusional 5-FU and bolus cisplatin i
        end
        70692
        exact text
        NCT02560298
        start
        70681
      2. context exact
        -list"><ol id="_420"><li>In the multicenter, randomized, phase II International Advanced Anal Cancer <a href="/clinicaltrials/NCT02560298">InterAACT</a> trial (NCT02560298), carboplatin (area under the curve 5) and weekly paclitaxel was compared with standard infusional 5-FU and bolus cisplatin in patients with advanced-stage ana
        end
        70726
        exact text
        NCT02560298
        start
        70715
      3. context exact
        ry studies in patients with stage IV disease suggest that alternative chemotherapy regimens (such as carboplatin and paclitaxel in the <a href="/clinicaltrials/NCT02560298">InterACCT</a> trial [NCT02560298]) or immune checkpoint inhibitors (as in <a href="/clinicaltrials/NCT02314169">NCI9673</a> [NCT02314169] and <a href="/clinic
        end
        82370
        exact text
        NCT02560298
        start
        82359
      4. context exact
        IV disease suggest that alternative chemotherapy regimens (such as carboplatin and paclitaxel in the <a href="/clinicaltrials/NCT02560298">InterACCT</a> trial [NCT02560298]) or immune checkpoint inhibitors (as in <a href="/clinicaltrials/NCT02314169">NCI9673</a> [NCT02314169] and <a href="/clinicaltrials/NCT02054806">KEYNOTE-028<
        end
        82404
        exact text
        NCT02560298
        start
        82393
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/b2aa40c79416a7e6ff.html
      source file sha256
      c54648d582057bfbec7e0e68f1a07a9ab6a29dd4c399f12d1b7bf097f6c59d27
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:29.122670+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      32139a41ddebb02ec050dd14be8192dc4da51ef1bbdfce96a9ed73332f6f7ce5
      source title
      Anal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: February 12, 2025
        datetime
        2025-02-12T12:00:00Z
        display
        February 12, 2025

    Preserved source evidence · Not medical advice